Angiosarcoma: adaptive designs leveraging vascular biology and antiangiogenic repurposing [0.03%]
血管生成为导向的适应性试验治疗肝内血管肉瘤
Elhadi Iich,Bavani Kannan,Yi Chye Law et al.
Elhadi Iich et al.
Introduction: Angiosarcoma is a rare and aggressive vascular malignancy characterized by substantial clinical and molecular heterogeneity. Grouping UV-associated cutaneous, radiation-associated, and visceral tumors within...
Addressing the therapeutic plateau in higher-risk myelodysplastic syndromes: rethinking trial design strategies [0.03%]
针对较高风险骨髓增生异常综合征治疗平台期的对策：重新思考临床试验设计策略
Pasquale Niscola,Maria Ilaria Del Principe,Fabio Efficace
Pasquale Niscola
The transcriptional landscape in thyroid cancer: current status of circulating biomarkers and liquid biopsy approaches [0.03%]
甲状腺癌的转录景观：循环生物标志物和液体活检方法的现状
Srabonti Ghosh,Avik Chakraborty,Bhakti Basu et al.
Srabonti Ghosh et al.
Introduction: Thyroid cancer is the most common endocrine malignancy, and despite advances in understanding its genomic drivers, significant challenges remain in predicting tumor behavior, therapeutic response, and diseas...
Portal vein resection in pancreatic cancer: from technical feasibility to biological patient selection [0.03%]
胰腺癌门静脉切除术：从技术可行性到生物选择患者
Takehiro Okabayashi,Motoyasu Tabuchi,Teppei Tokumaru et al.
Takehiro Okabayashi et al.
Introduction: Portal vein resection (PVR) has become an established component of pancreatic cancer surgery for selected patients with portal vein-superior mesenteric vein involvement. Although advances in surgical techniq...
An evaluation of retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal [0.03%]
评估retifanlimab-dlwr联合卡铂和紫杉醇以及单药治疗肛管鳞状细胞癌的效果
Tiffany Foo,Tharani Krishnan,Niall Tebbutt et al.
Tiffany Foo et al.
Introduction: Anal squamous cell carcinoma (SCC) is a rare cancer. Metastatic anal SCC is still a significant clinical challenge due to limited treatment options and poor outcomes. ...
Overcoming therapeutic resistance in biliary tract cancer: from resistance mechanisms to dynamic precision oncology - a narrative review [0.03%]
克服胆道癌治疗抵抗：从耐药机制到动态精准肿瘤学-综述文章
Takehiro Okabayashi,Motoyasu Tabuchi,Teppei Tokumaru et al.
Takehiro Okabayashi et al.
Introduction: Biliary tract cancer (BTC) is a biologically heterogeneous and highly aggressive malignancy with limited therapeutic options and poor survival. Although chemotherapy, targeted therapies, and immune checkpoin...
The burden of acute myeloid leukemia: an integrated review of clinical, economic, and patient-centered evidence [0.03%]
急性髓系白血病的负担：临床、经济和以患者为中心的证据的综合回顾
Amer M Zeidan,Ruizhi Zhao,Dina Christensen et al.
Amer M Zeidan et al.
Introduction: Acute myeloid leukemia (AML) is an aggressive hematologic cancer that accounts for approximately one third of all newly diagnosed leukemias annually in the United States (US), and is associated with high mor...
Association of neoadjuvant chemotherapy with outcomes in patients with elevated preoperative Ca 19-9 undergoing pancreatic ductal adenocarcinoma resection [0.03%]
新辅助化疗对术前CA 19-9升高胰腺导管腺癌切除患者结局的影响分析
Ewa Grudzińska,Magdalena Gajda,Sławomir Mrowiec
Ewa Grudzińska
Background: Serum Ca 19-9 is the most widely used biomarker in pancreatic ductal adenocarcinoma (PDAC). This study assessed the link between preoperative Ca 19-9, neoadjuvant chemotherapy (ChTNeo), and outcomes after panc...
Immune checkpoint inhibitors in people living with HIV and cancer: a Kaplan-Meier-derived individual patient data meta-analysis [0.03%]
人免疫缺陷病毒和癌症患者的免疫检查点抑制剂治疗：个体患者数据的kaplan-meier衍生汇总分析
Francisco Cezar Aquino de Moraes,Luis Henrique Rios Moreira Rego,Felipe Alves de Paiva et al.
Francisco Cezar Aquino de Moraes et al.
Introduction: Antiretroviral therapy has enabled people living with HIV (PLWH) to achieve near-normal life expectancy, but non-AIDS-defining cancers are increasingly frequent. Immune checkpoint inhibitors (ICIs) may be ef...
Predictive biomarkers of response in metastatic prostate cancer: paving the way for a new era of precision medicine [0.03%]
转移性前列腺癌响应预测生物标志物的研究：开启精准医疗新时代之路
Chiara Mercinelli,Fabrizio Di Costanzo,Christoph Oing et al.
Chiara Mercinelli et al.
Introduction: The therapeutic landscape for metastatic prostate cancer has expanded substantially over the last decade, yet treatment selection remains predominantly driven by clinical parameters rather than validated mol...